Navigation Links
Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
Date:9/13/2007

BIRMINGHAM, Ala., Sept. 13 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that it has licensed the rights to 4'-Thio-Ara-C, also known as SR9025, to Virium Pharmaceuticals, Inc. To date, six of Southern Research's anti-cancer drugs have received FDA approval and are on the market. Six others, including 4'-Thio-Ara-C, are in late stage preclinical testing or in early clinical trials.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070913/DCTH022 )

"Southern Research's agreement with Virium helps bring our work one step closer to the patients we hope to help. This is the first anti-cancer compound to be licensed after the completion of early clinical trials and we are eager to see it move through the pipeline," said John A. "Jack" Secrist, III, Ph.D., president and CEO of Southern Research. "We appreciate being able to work with a company when the success of our drug candidate is important to the success of the company."

The 4'-Thio-Ara-C compound, now registered to Virium as VP700, has shown activity against certain types of leukemia and autoimmune diseases. It is a third generation, novel nucleoside analog that has already completed two phase I trials.

"Southern Research's prestigious cancer program and international track record are well known and respected in the industry. The opportunity to work with a compound designed and developed by researchers at Southern Research is very exciting," said James Pachence, Ph.D., Virium Pharmaceuticals president and CEO. "Our strategy is to focus on targets that play key roles in diseases, and which can potentially be exploited in multiple indications beyond oncology. In addition to VP700, we are currently developing a portfolio of chemistry-driven HDAC inhibitors for cancer."

Southern Research will receive cash and stock in Virium, and will hold seats on the Virium Pharmaceuticals Scientific Advisory Board and the Board of Directors. The technical seat will be filled by Dr. Secrist and the Board seat (non-voting) will be filled by Dr. Nancy M. Gray, vice president of Corporate Development at Southern Research.

ABOUT SOUTHERN RESEARCH

Southern Research is a not-for-profit organization that conducts scientific research at facilities in Alabama, Maryland, Missouri and North Carolina. Southern Research provides contract and basic research in the fields of preclinical drug discovery and development, advanced engineering, and environmental and energy-related research. For more information, see http://www.SouthernResearch.org.

ABOUT VIRIUM PHARMACEUTICALS

Virium Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics with an initial focus on cancer. Virium has its lead cancer product, VP101, in clinical trials in the United States. VP101 is an HDAC inhibitor being developed in collaboration with the National Cancer Institute of the NIH. For more information, visit http://www.viriumpharma.com.

Media Contact:

Rhonda Jung Risa Goldman Burgess

Southern Research Institute Schwartz Communications

205-581-2317 781-684-0770

Jung@southernresearch.org southern@schwartz-pr.com


'/>"/>
SOURCE Southern Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Minneapolis company sets sights on southern Wisconsin
2. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
3. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
4. Control Your siRNA Research
5. Getting Started with MicroRNA Research
6. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
7. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
8. Research Organics
9. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
10. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
11. Research Tools for Analysis of ZAP-70
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the leader ... Lanphier , Sangamo,s president and chief executive officer, will ... Therapeutic ® development programs and an overview of ... Thursday, February 11, 2016, at the Leerink Partners 5 ... being held in New York . ...
(Date:2/4/2016)... 4, 2016 Beike Biotechnology, the ... attended a ceremony in late 2015 to mark their ... in 2016. --> --> ... for Personalized Cell Therapy" was hosted by the Shenzhen ... both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... , February 4, 2016 ... a biotechnology acceleration company is pleased to provide the following ... --> Over the last 3 months we have ... securities purchase agreements exceeding $1,000,000. As a result, we have ... Mannin Research Inc. license agreement and expect that development to ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... China , today announced that the ... February 4, 2016 a preliminary non-binding proposal letter, dated ... V-Ming ( Shanghai ) Investment Holdings Co., ... Shenzhen ) Fund Management Co., Ltd., Beijing ...
Breaking Biology Technology:
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Facial ... offering. --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has ... Facial Recognition Market 2016-2020" report to ... Markets ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ...
(Date:2/3/2016)... Calif. , Feb. 3, 2016 Vigilant ... Police Department in Missouri ... license plate reader (LPR) data from Vigilant Solutions. ... hit-and-run case in which the victim was walking out of a convenience ... parking space next to his vehicle, striking his vehicle ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):